Our tumor volume analysis indicated that the combination of mHAdLyp.sT, anti-PD-1 and anti-CTLA-4 antibodies (triple treatment) was the only group that significantly inhibited primary tumor progression when compared to the buffer group using a two-way ANOVA analysis at the end of this experiment (Day 23) (Fig. 7A, P < 0.001 vs buffer). Here, CTLA4 is linked to neoplasm.